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respectively. Cost-effectiveness ratio was $ 88.7 for oxyprogesteronicaproas and $ 
80.9 for dydrogesterone. ConClusions: Cost-effectiveness analysis shown, that 
the use of dydrogesterone is more effective and less costly for threatened abortion 
treatment in Ukraine. The results of pharmacoeconomic analysis will optimize the 
government, insurance companies and patients cost.
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objeCtives: The Dutch National Immunization Program offers the 10-valent pneu-
mococcal conjugate vaccine (PCV10). Also licensed for use in the infant population 
is the 13-valent PCV (PCV13). To update cost-effectiveness (CE) estimates of PCV13 
over PCV10, using current epidemiological and economic data. Methods: We mod-
eled vaccinating a birth cohort with either PCV10 or PCV13 (3+1 dose schedule), and 
calculated costs and effects linked to resulting disease. We modeled invasive pneu-
mococcal disease (IPD), non-invasive pneumonia and acute otitis media, and con-
sidered death and lifetime impairments after IPD. We calculated direct effects in 
the vaccinated cohort and indirect effects –herd immunity for the vaccine-type (VT) 
serotypes and replacement for the non-VT serotypes– in the rest of the population. 
Since no price is available, we use a price difference of € 11 per dose and vary this 
price difference in sensitivity analyses. Epidemiological and economic data are taken 
as current as possible. A set of scenarios explore different assumptions, including 
different sets of epidemiological data, assumptions on vaccine efficacy and indirect 
effects. Results: Taking only direct effects into account PCV13 cannot be consid-
ered cost-effective, unless the price difference is much lower than € 11 per dose. In 
three scenarios, PCV10 dominates PCV13; in the other scenarios the ICER is between 
€ 89000 and € 153000 per QALY gained. If indirect effects are also taken into account, 
the ICER of PCV13 compared to PCV10 is below € 20,000 per QALY for all scenarios. 
Scenarios do not have a large impact on the policy decision, unless we assume extra 
efficacy of PCV10 against non-typeable Haemophilus influenzae. ConClusions: 
Replacing PCV10 with PCV13 is not likely to be cost-effective in preventing invasive 
pneumococcal disease in young children. Taking potential benefits in elderly into 
account, PCV13 is likely cost-effective. The CE of PCV13 was highly sensitive for indi-
rect effects our analysis.
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objeCtives: To perform pharmacoeconomic evaluation of dienogest vs gonadotro-
phin-releasing hormone analogues (GnRHa) or dydrogesterone for endometriosis in 
Russia. Methods: Literature search did not reveale clinically significant differences 
in efficacy between dienogest 2 mg and GnRHa in terms of pain reduction associ-
ated with endometriosis. There was no difference in efficacy with dydrogesterone 
60 mg once daily and placebo. Cost-minimization analysis was used to assess and 
compare drug costs of dienogest 2 mg daily, GnRHa - most often used in Russia 
including triptorelin, leuprorelin, buserelin (with obligatory application of add-back 
therapy for all three GnRHa) and dydrogesterone. Costs were calculated for a period 
of 6 months. Results: Costs of endometriosis treatment per patient per 6 months 
were 1102€ for triptorelin, 1118€ for leuprorelin, 340€ for buserelin, 369€ for dydro-
gesterone and 295€ for dienogest. Dydrogesterone is less effective and more costly 
alternative in comparison with buserelin and dienogest. Among alternatives with 
the same efficacy dienogest is the most efficient option leading to savings from 74€ 
to 823€ per patient in 6 months. ConClusions: Using dienogest for treatment of 
endometriosis in Russia is as effective as using GnRHa but can lead to considerable 
cost savings because add-back therapy is not required.
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objeCtives: To provide the results from a cost-minimization (CM) model that com-
pares the use of dienogest with the use of GnRH antagonist (GnRHa) leuprorelin 
acetate, both for 6 months, in women with endometriosis-associated pelvic pain 
(EAPP) in Brazil. Methods: A(CM) model was developed in the form of a decision 
tree to mimic treatment sequence in Brazil. The analysis was conducted under the 
private and public payer perspectives, only direct costs were included, procedures 
and drug costs were obtain from Brazilian official databases of public and private 
health care system fees. This CM model compared different treatment pathways for 
women with EAPP and used a 50% improvement in pelvic pain as a definition of a 
treatment responder to elicit treatment duration. Treatment response assessment 
was at 12 week period. Two basic treatment pathways were defined: a two treatment 
sequence (2TS) and tree treatment sequence (3TS). The 2TS consists of: GnRHa/dien-
ogest followed by surgery. The 3TS consists of: GnRHa/dienogest, dienogest/GnRH 
as second treatment and surgery as final option. Subsequent treatments were only 
for patients that did not respond to previous treatment. Discount was not applied 
as costs occurred within 1 year period. Results: The CM model shows that for 
both treatment pathways and perspectives dienogest is a cost-saving alternative. 
Under private payer perspective for 2TS and 3TS: BRL 1020.42 VS BRL 2328.94 and 
BRL 1461.22 VS BRL 2377.52 for dienogest and GnRHa respectively. Under public 
payer perspective for 2TS and 3TS: BRL 882.74 VS BRL 768.13 and BRL 942.18 VS BRL 
856.77 for dienogest and GnRHa respectively. Efficacy for 2TS and 3TS are: 91.58% 
testing/delivering and definition of the CL test threshold. The values obtained were 
LR+ 3,98/LR- 0,33 (FN) and LR+ 2,22/LR- 0,54 (CL). For the whole hypothetical cohort 
the total costs of the FN and CL were 2,3 billion and 890 million, respectively. The 
difference of avoided hospitalizations between the tests was 244 for FN. ICER was 
BRL 5,834,35. ConClusions: Both diagnostic tests are important alternatives for 
the detection of premature birth in Brazil. Studies of prediction of preterm delivery 
using CL have important limitations beyond the fact that CL measure is an operator/
machine dependent procedure. In women with symptomatic preterm labor FN is a 
cost-effective test strategy for prediction of preterm births.
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objeCtives: To systematically review cost-effectiveness studies of vaccination 
against herpes zoster (HZ) and post-herpetic neuralgia (PHN). Methods: We 
searched MEDLINE and EMBASE databases for eligible studies until June 2013. We 
extracted information regarding model structure, model input parameters, and 
study results. We compared the results across studies by projecting the health and 
economic impacts of vaccinating 1 million adults over their lifetimes. Results: We 
identified 14 cost-effectiveness studies performed in North America and Europe. 
Results ranged from approximately US$10,000 to US$100,000 per quality-adjusted 
life years gained, though most studies in Europe concluded that zoster vaccination 
is likely to be cost-effective. All studies used similar model structure. Differences 
in results among studies are largely due to differing assumptions regarding dura-
tion of vaccine protection and a loss in quality of life associated with HZ and to 
a larger extent, PHN. In addition, studies found that vaccine efficacy against PHN, 
age at vaccination, and vaccine cost strongly influenced the results in sensitiv-
ity analysis. ConClusions: Our review generally supports the economic value of 
this preventive intervention, particularly in Europe, which will become increasingly 
important as population ages. Future research addressing key model parameters 
and cost-effectiveness studies in other parts of the world are needed.
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objeCtives: To determine the cost-effectiveness of using an online questionnaire 
(ePAQ-PF) in combination with a telephone consultation compared to standard 
care. Methods: All women, aged ≥ 18 years and referred to urogynaecology ser-
vices in Sheffield were eligible. Women completed ePAQ-PF online and then received 
a telephone consultation (intervention), or face-to-face consultation (standard 
care). Costs for ePAQ-PF completion and consultation were derived in a microcost-
ing study. Resource use data were collected at 6-months follow-up. The SF-12 was 
administered at baseline and follow-up. SF-6D estimates were used to calculate 
quality-adjusted life-years (QALYs). Patient experience was measured by the Patient 
Experience Questionnaire and Client Satisfaction Questionnaire. Results: A total of 
195 women were randomised. Consultation costs for the intervention group (£31.75) 
were lower than for the control (£72.17). The intervention group incurred greater 
direct costs and personal expenditure during follow-up. However lower costs asso-
ciated with productivity loss for the intervention group resulted in lower indirect 
costs per-patient. Mean total costs per-patient were £38.04 greater in the intervention 
group (£1,139.86) than the control (£1101.82). SF-6D scores reduced slightly during 
follow-up for the intervention group, and increased slightly for the control, resulting 
in QALY loss for the intervention group, and QALY gains for the control. Statistically 
significant gains in patient experience were identified for the intervention group, 
although in strict cost-utility terms the intervention was dominated by the control. 
Incremental costs and QALYs resulted in a negative incremental cost-effectiveness 
ratio (ICER). ConClusions: Although the intervention was not cost-effective com-
pared to the controls, there was a significant difference in an important aspect of the 
care process, which was not captured by the ICER. This highlights the importance of 
decision makers accounting for intervention effects that fall outside the conventional 
conceptualization of the QALY. Methods could be developed that allow non-health 
effects, such as process utility, to be incorporated into the QALY.
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objeCtives: Comparative evaluation the cost effectiveness of threatened abor-
tion treatment by two regimens: oxyprogesteronicaproas and dydrogesterone in 
Ukraine. Methods: Pharmacoeconomic analysis was based on the results of com-
parative randomized trial (Belousov Yu. B., Karpov O.I., Ailamazian E.K., 2008). Two 
regimens for threatened abortion treatment: oxyprogesteronicaproas and dydroges-
terone were evaluated. Treatment with dydrogesterone (20 mg per day or 2 tablets 
per day) was carried out during 8 weeks before closure forming placenta (56 days). 
Oxyprogesteronicaproas (250 mg per day) was used from 14 to 20 weeks of gestation 
(42 days). For determining the cost of therapy only the cost of drugs and auxiliary 
materials (syringes, alcohol) for both schemes were taken into account. The prices 
of drugs were taken from the information system “Drugs” of Company “Morion” 
(February, 2013, Ukraine). The currency ratio of UAH to dollar (USA) on 01.02.13 was 
8,12:1. As an indicator of efficacy the number of saved pregnancy after treatment 
was used. Results: The effectiveness of oxyprogesteronicaproas therapy was 
88.6%, and dydrogesterone - 96.3%, the cost of treatment was $ 78.63 and $ 77.96 
